

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<b>(51) International Patent Classification 5 :</b> <b>C08F 283/06, C07K 1/04</b>	<b>A1</b>	<b>(11) International Publication Number:</b> <b>WO 93/16118</b> <b>(43) International Publication Date:</b> 19 August 1993 (19.08.93)
<b>(21) International Application Number:</b> PCT/DK93/00051 <b>(22) International Filing Date:</b> 12 February 1993 (12.02.93) <b>(30) Priority data:</b> 07/835,277 13 February 1992 (13.02.92) US <b>(60) Parent Application or Grant</b> <b>(63) Related by Continuation</b> US 07/835,277 (CIP) Filed on 13 February 1992 (13.02.92) <b>(71) Applicant (for all designated States except US):</b> CARLSBERG A/S [DK/DK]; Vesterfælledvej 100, DK-1799 Copenhagen V (DK).	<b>(72) Inventor; and</b> <b>(75) Inventor/Applicant (for US only):</b> MELDAL, Morten, Peter [DK/DK]; Måløv Hovedgade 109, DK-2760 Måløv (DK). <b>(74) Agent:</b> HOFMAN-BANG & BOUTARD A/S; Adelgade 15, DK-1304 Copenhagen K (DK). <b>(81) Designated States:</b> AU, BR, CA, JP, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE). <b>Published</b> With international search report.	
<b>(54) Title:</b> POLYETHYLENE OR POLYPROPYLENE GLYCOL CONTAINING POLYMER  <b>(57) Abstract</b> <p>A crosslinked polyethylene or polypropylene glycol containing polymer which has a unique spatial structure and can be designed especially for application as a chromatographic resin or as a solid support for the synthesis of peptides, oligonucleotides or oligosaccharides or as a substrate for the immobilization of proteins. The polymer is formed by radical copolymerization of derivatized polyethylene glycol or polypropylene glycol bis-end substituted with a moiety selected from the group consisting of acryloylalkyl, acryloylaryl, acrylamidoalkyl and acrylamidoaryl with an acrylic amide, nitrile or ester. When it is to be used as a solid support or immobilization substrate, the polymer will incorporate a spacer comprising functional groups for the attachment of peptides, proteins, nucleotides or saccharides such as those selected from the group consisting of amino, alkylamino, hydroxy, carboxyl, mercapto, sulfeno, sulfinio, sulfo and derivatives thereof.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	FR	France	MR	Mauritania
AU	Australia	GA	Gabon	MW	Malawi
BB	Barbados	GB	United Kingdom	NL	Netherlands
BE	Belgium	GN	Guinea	NO	Norway
BF	Burkina Faso	GR	Greece	NZ	New Zealand
BG	Bulgaria	HU	Hungary	PL	Poland
BJ	Benin	IE	Ireland	PT	Portugal
BR	Brazil	IT	Italy	RO	Romania
CA	Canada	JP	Japan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SK	Slovak Republic
CI	Côte d'Ivoire	LJ	Liechtenstein	SN	Senegal
CM	Cameroon	LK	Sri Lanka	SU	Soviet Union
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	MC	Monaco	TG	Togo
DE	Germany	MG	Madagascar	UA	Ukraine
DK	Denmark	ML	Mali	US	United States of America
ES	Spain	MN	Mongolia	VN	Viet Nam
FI	Finland				

## Polyethylene or polypropylene glycol containing polymer

This invention relates to a crosslinked polyethylene or polypropylene glycol containing polymer which has a unique spatial structure and can be designed especially for application as a chromatographic resin or as a solid support for the immobilization of proteins or for the synthesis of peptides, oligonucleotides or oligosaccharides.

### BACKGROUND OF THE INVENTION

When solid phase peptide synthesis was first introduced by Bruce Merrifield<sup>1</sup> it was performed on a support of 2% cross linked polystyrene allowing the preparation of a pentapeptide by a batchwise synthesis protocol. This invention formed the basis of a technique, which has since been subjected to continuous refinement. With the synthesis of longer peptides it soon became apparent that the cross linking of the resin had to be optimized. The best results were obtained with the 1% cross linked resin still used in the batch synthesis today<sup>2</sup>. A more polar dimethyl acrylamide resin suitable for peptide synthesis in polar solvents like DMF was developed in Sheppards laboratory<sup>3</sup>.

With the introduction of Fmoc-based solid phase synthesis<sup>4,5</sup> the much more efficient continuous flow process became a realistic alternative to the batch method. The available batch resins were however not flow stable and collapsed after a few synthesis cycles. It was well established that increased cross linking while increasing the stability of the resin would not lead to useful properties for peptide synthesis. The first flow stable synthesis resin was obtained by polymerization of the soft polydimethyl acrylamide gel inside a solid matrix of supporting kieselguhr<sup>6</sup>. This ingenious invention allowed the packing of columns, which were completely flow stable throughout the synthesis.

The principle was refined by replacing the irregular kieselguhr with a more regular rigid 50% cross linked polystyrene sponge containing a grafted polydimethyl acrylamide gel<sup>7</sup>.

5

At the same time a technique was developed for grafting polyethylene glycol on to a 1% crosslinked polystyrene<sup>8</sup>. The resulting resins were monodisperse, spherical and, more importantly, flow stable. A more controlled grafting by direct substitution of the functional groups in the polystyrene with modified polyethylene glycol carrying an amino group has also been described<sup>9</sup>. Polystyrene grafted to films of polyethylene has been used for synthesis of peptides under nonpolar conditions<sup>10</sup> and polyhydroxypropyl acrylate coated polypropylene<sup>11</sup> and the natural polymer, cotton, has shown some promise as supports under polar conditions<sup>12</sup>.

20

A preparation of a polymer with short crosslinking PEG chains ( $n=6$ ) was attempted by inverse suspension polymerization of polyethylene glycol methacrylate macromonomers<sup>13</sup>; but with the high PEG content (60% crosslinker) the polymer became semicrystalline already during the polymerization reaction. The described polymer of short chain PEG crosslinked by means of ester linkages<sup>13</sup> was not suited for peptide synthesis.

25

#### SUMMARY OF THE INVENTION

30


The present invention provides a novel crosslinked PEG-containing polymer designed especially for application as a flow stable, highly polar solid support for solid phase synthesis. The polymer was constructed to be stable under continuous flow conditions and to be transparent with no absorbance in the aromatic region to allow the spectrophotometric monitoring of reaction within the resin. It should furthermore form a highly branched polymer network, with

35

good swelling in polar solvents allowing uncomplicated assembly of even long peptides. The change in swelling should be insignificant throughout the synthesis, and the density of the resin should allow multiple column peptide synthesis. Therefore the resin was designed to be highly polar assisting peptide solvatization, allowing penetration of polar components into the interior of the beads and preventing adherence to plastics. Finally easy preparation and low cost starting materials were considered to be very important for a successful synthesis resin.


This is achieved with the polymer according to the invention which is formed by radical copolymerization of derivatized polyethylene glycol or polypropylene glycol bis-end substituted with a moiety selected from the group consisting of acryloylalkyl, acryloylaryl, acrylamidoalkyl and acrylamidoaryl with an acrylic amide, nitrile or ester.

A more specific polymer according to the invention is formed by copolymerization of a derivatized polyethylene glycol of the formula




I

wherein n is an integer of from 4 to 2000, q is zero or 1, and R is



where s, t and u each is zero or an integer of 1-10, and each R' is H, alkyl, aralkyl or aryl, said aralkyl or aryl optionally being ring substituted with alkyl, hydroxy, mercapto, nitro, amino, mono- or dialkylamino, or halogen, with an acrylic compound of the formula

4




III

wherein  $R^1$  is  $-\text{CY}-\text{X}-\text{R}^5$  or  $-\text{CN}$ , and  $R^2$ ,  $R^3$  and  $R^4$  each is H, alkyl, aralkyl, aryl,  $-\text{CY}-\text{X}-\text{R}^5$  or  $-\text{CN}$ , where Y is O or S, X is O, S or  $\text{NR}^6$ ,  $R^5$  is alkyl, aralkyl or aryl, and  $R^6$  is H or  $R^5$ , and optionally with a spacer molecule comprising functional groups for the attachment of peptides, proteins, nucleotides or saccharides.


When it is to be used as a solid support for the synthesis of peptides, oligonucleotides or oligosaccharides or as a substrate for the immobilization of proteins, the polymer according to the invention will incorporate a spacer comprising functional groups for the attachment of peptides, proteins, nucleotides or saccharides such as those selected from the group consisting of amino, alkylamino, hydroxy, carboxyl, mercapto, sulfeno, sulfinio, sulfo and derivatives thereof.

A polymer according to the invention which is especially suited for application as a solid support for continuous flow or batchwise synthesis of peptides, oligonucleotides or oligosaccharides is formed by copolymerization of a derivatized polyethylene glycol of the formula I, wherein n, q and R are as defined above, with an acrylamide of the formula



3

and with a spacer molecule of the formula




I I

wherein  $m$  is an integer of from 4 to 2000, and  $q$  and  $R$  are as defined for formula I above.

Preferred values of  $n$  in formula I above are between about 20 and about 90, i.e. the compound is a derivative of PEG<sub>1000</sub> to PEG<sub>4000</sub>. Preferred values of  $m$  in formula II are between about 4 and about 45, i.e. the compound is a derivative of PEG<sub>200</sub> to PEG<sub>2000</sub>.

A preferred polymer according to the invention is composed of 60% of bis-2-acrylamidoprop-1-yl-PEG<sub>1900</sub> (1), 20% of 2-acrylamidoprop-1-yl[2-aminoprop-1-yl]-PEG<sub>300</sub> (2) and 20% of *N,N*-dimethyl acrylamide (3).

Such polymers according to the invention may again be derivatized with any of the linkers normally used in peptide synthesis. Four well characterized linkers for peptide synthesis are 4-[fluorenylmethyloxycarbonyl(2,4-dimethoxyphenyl)methyl]phenoxyacetic acid of the formula



and 4-hydroxymethylphenoxyacetic acid<sup>20</sup> which are both cleaved in TFA producing peptide amides and peptide acids,

respectively, 4-hydroxymethylbenzamide<sup>20</sup> which is cleaved with 0.1 M NaOH, and 4-hydroxymethyl-3-nitrobenzamide<sup>2</sup> which is cleaved by photolysis. The compound 4 is also called 4-[Fmoc-amino(2,4-dimethoxyphenyl)methyl]phenoxyacetic acid  
5 where "Fmoc" signifies "fluorenylmethyloxycarbonyl".

The present invention also relates to a solid support for continuous flow or batchwise synthesis of peptides, oligo-  
10 nucleotides or oligosaccharides said support comprising a polymer according to the invention as described above. A particular feature of the support according to the invention is that it is also suitable for syntheses involving enzymatic reactions.

15 The invention also relates to a solid support for enzymatic synthesis of oligosaccharides with glycosyltransferases said support comprising a polymer according to the invention as described above.

20 Further, the invention relates to a solid support for the immobilization of proteins said support comprising a polymer according to the invention as described above.

25 Still further, the invention relates to a resin for application in chromatographic separations such as gel-permeation chromatography and ion-exchange chromatography said resin comprising a polymer according to the invention as described above.

30 The present invention also relates to a method of continuous flow or batchwise synthesis of peptides, oligonucleotides or oligosaccharides wherein the peptide, oligonucleotide or oligosaccharide during the synthesis is attached to a solid support comprising a polymer according to the invention as  
35 described above and at the end of the synthesis is cleaved from said solid support. Due to the particular features of the polymer according to the invention this method also



lends itself to syntheses involving enzymatic reactions and specifically to an enzymatic synthesis of an oligosaccharide with a glycosyltransferase.

5 The invention also relates to a method of immobilizing a protein wherein the protein is attached to a solid support comprising a polymer according to the invention as described above.

10 Further, the invention relates to a method of performing chromatographic separations which comprises the use of a chromatographic resin comprising a polymer according to the invention as described above.

15 In the following the polymer according to the invention is for short termed the PEGA resin or PEGA polymer.

#### BRIEF DESCRIPTION OF THE DRAWINGS

20 Fig. 1 is a schematic representation of the PEGA polymer where the polyacrylamide backbones are shown vertically and the crosslinking PEG moieties are shown horizontally.

25 Fig. 2 illustrates a fragment of the chemical structure of the PEGA polymer.

30 Fig. 3 illustrates at the top the sequence 5 of the test decapeptide fragment from acyl carrier protein 65-74 synthesized in the Example and below it a graph presenting transmission spectra of three of the acylation reactions and a HPLC trace of the crude product.

35 Fig. 4 illustrates the large but limited swelling of the PEGA polymer.

#### THE STRUCTURE OF THE PEGA RESIN

The PEGA polymer has a unique structure compared with other polymers due to the extremely high content of crosslinking long chain PEG. The polymer form a highly and uniformly branched network of very long flexible interweaving chains which allows a high degree of swelling to a specific and very well defined bead size. The structure may be described by the schematic representation shown in Fig. 1 where the polyacrylamide backbones are shown vertically and the crosslinking PEG moieties are shown horizontally. Branch points are indicated by a dot.

The good swelling and the long and flexible chains yield a gel-like and yet hard polymer with very good diffusion properties in the comb-like interior. The very high content and dominating influence of the PEG on the properties of the polymer yield a resin which swells equally well in polar solvents, e.g. water, N-N-dimethyl formamide, acetonitrile and trifluoroacetic acid, and unpolar solvents, e.g. dichloromethane and chloroform.

Thus, the base and acid stable polymer according to the present invention is characterized by its very powerful swelling potential in many solvents of very different polarity (e.g.  $\text{CH}_2\text{Cl}_2$  or water), derived from the high solvation energy of the major polymer component, polyoxyethylene (PEG) in these solvents. This amphipathic nature of PEG is due to its flexibility and ability to form folded structures with either polar or hydrophobic surfaces. The use of a high content (60-70%) of well defined diacrylamido-PEG for the crosslinking of the polymer result in a uniform and relatively large swelling volume (e. g. 13 fold the volume of the dry polymer with PEG 1900) in most solvents. The principle of the large but limited swelling is demonstrated in Fig. 4 where the folded PEG is behaving as folded springs which are stretched out completely by the large force of PEG solvation to form a completely permeable polymer with large and uniform internal cavities allowing

for mass transport and chemical reactions to be carried out inside the polymer with kinetic parameters similar to those observed in solution.

5 The extremely polar character, the swelling in water and the large pores of the gel-like polymer allows the use of enzymes in reactions on the support. Thus it was demonstrated that a  $\beta$ -1-4-galactosyltransferase could transfer galactosyl-UDP to a resin bound N-acetyl glucosamine. These properties  
10 ties are currently being further evaluated.

A fragment of the chemical structure of the polymer is presented in Fig. 2. Other types of spacers can be derivatized with acryloyl chloride and incorporated to introduce  
15 the functional group, which can be an amino group, a carboxylic, phosphonic or sulfonic acid group, a mercapto or a hydroxy group, into the resin. Alternatively it may be omitted completely for a non functionalized resin. This can for example be applied in gel permeation chromatography, and  
20 the resin with charged groups can be applied in ion exchange chromatography. This is possible because this resin in contrast to other gel resins of the polydimethyl acrylamide and the polystyrene type is flow stable.

25 The process for producing the polymer of the invention is unique in that an aminofunctionalized, flow stable, highly swelling polymer with a constant swelling volume is obtained in a single radical polymerization step. The application of the efficient acrylamide-based radical polymerization allow  
30 the formation of completely uniform spherical beads with a narrow size distribution (175-200  $\mu$ m) needed for fast solid phase chemical reactions carried out in the flow through mode. The polymer contains no ester bonds, and this is a requirement for a polymer which is used in a variety of  
35 chemical reactions involving strong and nucleophilic bases (e. g. piperidine or aqueous solutions of alkali metal hydroxides) as well as strong acids (e. g. trifluoroacetic

acid or HF).

#### EXAMPLE 1

- 5 Copolymerization of bis-2-acrylamidoprop-1-yl-PEG<sub>1900</sub> (1), 2-acrylamidoprop-1-yl[2-aminoprop-1-yl]-PEG<sub>300</sub> (2) and N,N-dimethyl acrylamide (3) afforded a resin which fulfilled most of the above criteria. Compound 1 was prepared in 67% yield by reaction of bis-2-aminoprop-1-yl-PEG<sub>1900</sub> dissolved in dichloromethane and triethylamine (2 eqv.) at 0 °C with acryloylchloride (2 eqv.). The mixture was filtered after 10 30 min and concentrated to half the volume. Diethyl ether (4 volumes) was added and the product crystallized with a small amount of Et<sub>3</sub>N·HCl. It was collected by filtration, 15 washed with diethyl ether, dried and characterized by <sup>1</sup>H-NMR spectroscopy. A similar procedure with dropwise addition of acryloylchloride (1 eqv.) to triethylamine and bis-2-aminoprop-1-yl-PEG<sub>300</sub> in dichloromethane was employed for the preparation of compound 2. The product could not be crystal- 20 lized but was stirred several times with diethyl ether at 20 °C and decanted after cooling to -30 °C. Residual diethyl ether was removed in vacuo yielding 74% of product containing one acrylamido- and one amino group for each PEG molecule according to the integration of a <sup>1</sup>H-NMR spectrum.
- 25 <sup>1</sup>H-NMR in CDCl<sub>3</sub>, relative to CHCl<sub>3</sub> = 7.30 ppm, δ ppm(J Hz) for 1; Acrylamide; 6.33 (17.0, 2H, CH<sub>2</sub>-trans), 5.64(10.0, 2H, CH<sub>2</sub>-cis), 6.19(17.0, 10.0, 2H, CH); 2-amidopropyl; 1.24(6.6, 6H, CH<sub>3</sub>); 4.19-4.16(m, 2H, CH) 3.50(6.6, 10.6, CH<sub>2</sub>) 3.66(m, 190H, PEG), 2 had similar 30 chemical shifts and integrated correctly. Et<sub>3</sub>N·HCl could be removed from 1 by partition between CH<sub>2</sub>Cl<sub>2</sub> and water. The bisacrylamido-PEG<sub>300</sub> is insoluble in water and can therefore be removed from 2 before polymerization.
- 35 The syrup was estimated to contain approximately 15% of respectively the bisacrylamido- and the diamino-PEG<sub>300</sub>-derivatives.

The polymer was prepared in a granulated and in a beaded form both with a high content of PEG and with 20% N,N-dimethyl acrylamide added to avoid neighboring branching points in the acrylic polymer. The 20% of the mono amine 3 was added to yield a substitution of approximately 0.1 mmol/ml in the final swollen resin. Thus 1 (3 g), 2 (1 g) and 3 (1 mL) were dissolved in DMF (5 mL) and water (3 mL). The solution was purged with argon for 15 min. Ammonium peroxydisulfate (800 mg) in water (2 mL) was added. The solution was stirred for 5 min and then left for 5 h to polymerize. It was cut up and granulated through a fine stainless steel net with mask size 0.8 mm. Fines were decanted 3 times with ethanol (100 mL). It was washed on a filter with water (100 mL), sodium hydroxide (1 M, 50 mL), water (200 mL), DMF (50 mL), and ethanol (100 mL) and sucked dry. The resin was lyophilized affording 84% yield. The granulated resin swelled to 6 mL/g in DMF. It was swelling to a similar degree in dichloromethane, in TFA, in alcohols and in water, thus showing a wide scope for applications.

Alternatively the resin was prepared in a beaded form essentially as described by Kanda et al.<sup>14</sup>. The beaded polymer was treated as described above yielding 70% of fine beads swelling to 8 mL/g in DMF. The beaded resin was best handled as a slurry in DMF since the dry beads had a tendency to adhere to glass and metal. It did however not at all adhere to plastics and teflon.

The beaded resin (200 mg) was packed into a glass column and derivatized with Fmoc-Gly-O-Pfp and then 4-[Fmoc-amino(2,4-dimethoxyphenyl)methyl]phenoxyacetic acid, (4; Rink linker<sup>15</sup>, 160 mg) by the TBTU procedure<sup>16</sup>. After 20 min Dhbt-OH was added indicating complete reaction, and acetic anhydride (40 µl) was added. The resin was deprotected and the test decapeptide fragment from acyl carrier protein 65-74 (5; Fig. 3) was synthesized by the Dhbt ester method<sup>17</sup> on a custom made peptide synthesizer the reaction being followed

with a solid phase spectrophotometer<sup>18</sup>. In Fig. 3 transmission curves are shown for three of the acylation reactions. The peptide was isolated in 31 mg crude product yield by cleavage with 92% TFA, 3% anisole, 1% EDT, 1% thioanisole and 3% H<sub>2</sub>O. The recorded reaction times were compared to the reaction times for the same synthesis on the kieselguhr supported polyamide resin<sup>19</sup> presented in brackets: Gly, 2 min; Asn, 3 min (30 min); Ile, 43 min (60 min); Tyr, 3 min (36 min); Asp, 3 min (20 min); Ile, 73 min (30 min), Ala, 5 min (20 min); Ala, 5 min (20 min); Gln, 10 min (60 min); Val, 65 min (> 1440 min). The last addition of Val to Gln is known to be particularly difficult due to aggregation in the resin allowing complete acylations only with precautions and addition of hydrogen bond breaking agents. With the PEGA resin it was complete in 65 min, and HPLC and amino acid analysis and sequence analysis showed no presence of the desvaline peptide usually observed in these syntheses. Similar reaction times and results were obtained with the granulated resin.

20

## EXAMPLE 2

### Preparation of a beaded 1900/300-PEGA resin

#### 25 Bis-acrylamidopropyl-PEG<sub>1900</sub> (1)

Bis-aminopropyl-PEG<sub>1900</sub> (300 g, 150 mmol, 300 mmol NH<sub>2</sub>) was dissolved in triethylamine (41,7 ml, 300 mmol) and dichloromethane (350 ml) and acryloylchloride (24.37 ml, 300 mmol) was slowly added with cooling at 0-15 °C over a period of 40 min with efficient stirring. Then the mixture was stirred for 20 min. After filtration and washing with CH<sub>2</sub>Cl<sub>2</sub> (100 ml) the combined filtrate was evaporated at 10 and 0.1 torr (40 °C). Et<sub>2</sub>O (800 mL) was added. The product was stirred and then cooled and allowed to crystallize at -78 °C with stirring and then left overnight at -20 °C. Filtration and grinding up with more Et<sub>2</sub>O (500 ml) followed by filtration

and washing with Et<sub>2</sub>O (300 ml) afforded 308g of product.

**Monoacrylamidopropyl-(aminopropyl)-PEG<sub>300</sub> (2)**

5 Bis-aminopropyl-PEG<sub>300</sub> (100 ml, 0.5 mole NH<sub>2</sub>-groups) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> (50 ml) and acryloylchloride (10 ml, 0.12 mole) dissolved in CH<sub>2</sub>Cl<sub>2</sub> (150 ml) was slowly added under argon at 0 °C with cooling on ice over a period of 90 min. The mixture was stirred for 20 min and evaporated first at 10 torr and then at 0.1 torr to yield a thick syrup. This crude mixture was used for the polymerization.

**Polymerization**

15 1 (150 g) and 2 (100 g) were dissolved in water (570 ml) stirring with a stream of argon. N,N-Dimethylacrylamide (fresh, 30 g) was added and flushing was continued for 5 min. Hexane (1685 ml) and CCl<sub>4</sub> (1140 ml) were mixed in the polymerization apparatus and argon was flushed through. The apparatus was heated to 65-77 °C. (NH<sub>4</sub>)<sub>2</sub>S<sub>2</sub>O<sub>8</sub> (4.2 g) in H<sub>2</sub>O (15 ml) was added to the aqueous polymerization mixture at 20 °C with argon stirring. Sorbitan monolaurate (3.6 g in 15 ml DMF) was added and the mixture was transferred to the apparatus stirring 550-600 rpm (T=50 °C). After 2 min stirring at 550 rpm N,N,N',N'-tetramethyl ethylenediamine (12 ml) was added and the stirring was continued while the temperature was increased to 65 °C. After 30 min the stirring was increased to 600 rpm and continued for 4 h. The resin was cooled and filtered in a 12 cm \* 35 cm filter with a valve, washed with methanol (1 L) and water (2 L). It was passed through a steelnet, transferred back to the filter and washed with water (8 L) and methanol (2.5 L). The methanol may be removed by lyophilization.

35 Solid-phase Synthesis. General Procedure. - Synthesis of the glycopeptides was performed in DMF with a custom-made, fully automatic, continuous-flow peptide synthesizer or by the

plastic syringe technique (as described below) using PEGA-resin{358} (0.07 mmol/g). Amino acids were coupled as their Pfp esters (3 equiv.) with Dhbt-OH (1 equiv.) added as an auxiliary nucleophile or as their Dhbt-esters (3 equiv.).

- 5 The sidechains were protected with Bu<sup>t</sup> for serine, threonine and tyrosine. N<sup>o</sup>-Fmoc deprotection was effected by treatment with 20% piperidine in DMF for 30 min and the acylation times were determined with a solid-phase spectrophotometer at 440 nm. Glycine was coupled directly on to the resin
- 10 followed by coupling of the Rink-linker by the TBTU procedure.{413} The first amino acid was coupled and unchanged amino groups were capped by addition of acetic anhydride before coupling of the second amino acid. After deprotection of the last amino acid the resin was removed from the
- 15 column, washed with dichloromethane and lyophilized overnight. The cleavage of the peptide or the glycopeptide from the solid support was performed by treatment with a mixture of TFA, water and scavengers as described in detail under the individual peptides. After cleavage the resin was poured
- 20 on to a glass filter and washed three times with TFA followed by 95% aqueous acetic acid. The combined filtrates were concentrated and the residue was solidified by several triturations with diethylether which was decanted. Residual solvent was removed under reduced pressure and the peptide
- 25 was purified by preparative HPLC.

The purified acetylated glycopeptide was dissolved in dry methanol (1 mg cm<sup>-3</sup>) and 1 mol dm<sup>-3</sup> sodium methoxide in methanol was added until a wetted pH-paper indicated pH 11.

30 The mixture was stirred at ambient temperature for 2 h, neutralized with small pieces of solid CO<sub>2</sub> and concentrated. The residue was dissolved in water (1 mg cm<sup>-3</sup>) and purified by preparative HPLC.

- 35 Solid-phase synthesis. Plastic syringe technique. - Peptide 28 and glycopeptide 29 were synthesized by use of the plastic syringe technique, which is a simple and cheap



alternative to automatic peptide synthesizers. The technique is exemplified here with the synthesis of dipeptide, H-Asn-Phe-NH<sub>2</sub>, 28. A 20 cm<sup>3</sup> disposable plastic syringe A (without piston) was fitted with a sintered teflon filter (pore size 70 µm) and the outlet connected to the outlet of a 50 cm<sup>3</sup> plastic syringe B via a teflon tube with luer adapters. Syringe B was used as a waste syringe to remove solvents. PEGA-resin (0.5 g, 0.07 mmol/g) was placed in syringe A and allowed to swell in DMF (10 cm<sup>3</sup>) which was carefully added from the top and removed from the bottom by suction with syringe B. N<sup>α</sup>-Fmoc-L-Gly-OPfp (49 mg, 0.105 mmol) and Dhbt-OH (5.7 mg, 0.035 mmol) was dissolved in DMF (4 cm<sup>3</sup>) and the mixture poured on to the resin. After coupling the resin was rinsed with DMF (8 x 4 cm<sup>3</sup>) before N<sup>α</sup>-Fmoc deprotection. Piperidine in DMF (20%, 2 x 4 cm<sup>3</sup>) was added to the resin in two steps. The first portion was sucked quickly through the resin followed by addition of the second portion, which was removed after 30 min. After thorough rinse with DMF (8 x 4 cm<sup>3</sup>) Rink-linker (57 mg, 0.105 mmol), TBTU (34 mg, 0.105 mmol) and N-ethyl-morpholine (26 mm<sup>3</sup>, 0.21 mmol) was dissolved in DMF (4 cm<sup>3</sup>) and added to the resin. After 2 h the resin was rinsed with DMF (8 x 4 cm<sup>3</sup>) before N-Fmoc deprotection and coupling of N<sup>α</sup>-Fmoc-L-Phe-OPfp and N<sup>α</sup>-Fmoc-L-Asn-OPfp as described above. After final deprotection the peptide-resin was rinsed with dichloromethane and lyophilized before cleavage of the peptide from the solid support with TFA/ethanedithiol/thioanisole/anisole/water (67/1/1/2.7/-2.7) to yield crude dipeptide 28.

H-Asn-Phe-NH<sub>2</sub>, 28 and H-Asn(2,3,6-tri-O-acetyl-4-O-(2,3,4,6-tetra-O-acetyl-β-D-galactopyranosyl)-β-D-glucopyranosyl)-Phe-NH<sub>2</sub>, 29. Title compounds 28 and 29 were synthesized by the plastic syringe technique as described. In the synthesis of 29 H-Phe-Resin was coupled with 27 (80 mg, 0.07 mmol) to give peptide-resin A.

d-Ala-Ser-Thr-Thr-Thr-Asn(4-O-α-D-glucopyranosyl-β-D-glu-

cose)-Tyr-Thr-NH<sub>2</sub>, 31. The solid-phase synthesis was carried out on a custom-made, fully automatic, continuous-flow peptide synthesizer, according to the general procedure as described above. PEGA-resin (0.5 g, 0.07 mmol/g) was used. Two equivalents of 7 (80 mg, 0.07 mmol) were used, with one equivalent of Dhbt-OH (5.7 mg, 0.035 mmol). After completed coupling (4 h) residual 7 was recovered (48 mg, 0.04 mmol). d-Alanine was incorporated as the free acid by the TBTU procedure.<sup>{413}</sup> After cleavage from the resin with TFA/ethanedithiol/thioanisole/anisole/water (67/1/1/2.7/2.7) (22 cm<sup>3</sup>, 2 h, ambient temperature) and trituration with ether, the solidified crude glycopeptide, hepta-O-acetate 30 (36 mg, 87% - based on 7) was purified by preparative HPLC using 10% solvent B for 20 min, followed by a linear gradient of 10-60% solvent B during 100 min (retention time 59.6 min). The yield of 30 was 11 mg (27%). Deacetylation with sodium methoxide as described above, followed by purification by preparative HPLC using 0% solvent B for 10 min, followed by a linear gradient of 0-30% solvent B during 60 min (retention time 30.6 min) afforded pure title compound 31 (5.5 mg, 17%). <sup>1</sup>H and <sup>13</sup>C NMR data are presented in Table 7 and Table 8, respectively. Amino acid analyses (theoretical value in parenthesis): Ala 1.00 (1), Asn 0.88 (1), Ser 1.06 (1), Thr 4.17 (4), Tyr 0.89 (1).

Table 7. <sup>1</sup>H-NMR chemical shifts (ppm) and coupling constants (Hz) of 32<sup>a</sup> and 31<sup>b</sup>, measured at 500 MHz and 600 MHz at 300 K.  
Reference: Internal acetic acid at 2.03 ppm.

	32	31	32	31	
ala <sup>1</sup> α	4.160 (7.0)	4.162 (7.1)	Asn <sup>5</sup> N <sup>6</sup> H	8.325 (8.0)	8.371 (7.6)
β	1.536	1.539	α	4.694	4.742
SeI <sup>2</sup> N <sup>6</sup> H	8.690 (6.8)	8.708 (6.9)	β	2.762 (6.5;15.5)	2.848 (6.2;16.1)
α	4.560	4.568	β <sup>1</sup>	2.669 (7.5)	2.762 (7.1)
β	3.911 (5.5;11.5)	3.911 (5.9;11.5)	N <sup>6</sup> H	7.489	8.791 (8.8)
β <sup>1</sup>	3.864 (5.0)	3.868 (5.2)	N <sup>6</sup> H <sup>1</sup>	6.819	-
Thr <sup>2</sup> N <sup>6</sup> H	8.306 (8.0)	8.325 (7.8)	Tyr <sup>7</sup> N <sup>6</sup> H	8.183 (7.0)	8.205 (7.0)
α	4.464 (4.5)	4.471 (4.3)	α	4.600	4.603
β	4.279 (6.5)	4.284 (6.5)	β	3.045 (7.5;14.0)	3.052 (7.0;14.0)
γ	1.202	1.206	β <sup>1</sup>	2.961 (8.0)	2.969 (8.0)
Thr <sup>4</sup> N <sup>6</sup> H	8.183 (7.0)	8.215 (7.5)	δ,δ <sup>1</sup>	7.110 (8.5)	7.114 (8.4)
α	4.421 (4.5)	4.430 (4.6)	e,e <sup>1</sup>	6.807	6.812
β	4.230 (6.5)	4.243 (6.4)	Thr <sup>4</sup> N <sup>6</sup> H	7.977 (8.0)	8.029 (8.0)
γ	1.177	1.179	α	4.230 (4.0)	4.240
Thr <sup>5</sup> N <sup>6</sup> H	8.100 (7.5)	8.119 (7.6)	β	4.204 (6.5)	4.212 (6.3)
α	4.297 (4.5)	4.298 (4.7)	γ	1.130	1.143
β	4.108 (6.5)	4.097 (6.3)	CONH	6.968	6.978
γ	1.095	1.088	CONH <sup>1</sup>	7.030	7.063

	H-1	H-2	H-3	H-4	H-5	H-6	H-6 <sup>1</sup>
31 α-D-glucopyra- nosyl	5.367 (3.8)	3.561 (9.8)	3.672 (9.5)	3.395 (9.5)	3.697	3.864 (11.4)	3.748
β-D-glucopyra- nose	4.90 <sup>c</sup>	3.389 (9.2)	3.798 (8.7)	3.625	3.743	3.832 (1.7;12.2)	3.738 (5.1)

a 5.2 mg in 10% CD<sub>3</sub>COOD/H<sub>2</sub>O (600 mm<sup>2</sup>, pH 2.27).

b 4.6 mg in 10% CD<sub>3</sub>COOD/H<sub>2</sub>O (600 mm<sup>2</sup>, pH 2.41).

c Approximate value.

	32	31	32	31
ala <sup>1</sup>	α	49.5	49.6	Asn <sup>6</sup>
	β	16.8	16.9	
Ser <sup>2</sup>	α	55.9	55.9	Tyr <sup>7</sup>
	β	61.4	61.4	
Thr <sup>3</sup>	α	59.3	59.3	
	β	67.2	67.3	
	γ	19.0	19.0	
Thr <sup>4</sup>	α	59.3	59.3	
	β	67.3	67.3	Thr <sup>8</sup>
	γ	19.0	19.0	
Thr <sup>5</sup>	α	59.3	59.3	
	β	67.3	67.4	
	γ	19.0	19.0	

	C-1	C-2	C-3	C-4	C-5	C-6
31 $\alpha$ -D-glucopyranosyl	99.9	72.0	76.8	69.7	73.2	60.8
$\beta$ -D-glucopyranose	79.3	72.0	77.2	76.4	72.9	60.8

a 15.0 mg in 10% CD<sub>3</sub>COOD/H<sub>2</sub>O (600 mm<sup>3</sup>, pH 2.72).  
b 4.6 mg in 10% CD<sub>3</sub>COOD/H<sub>2</sub>O (600 mm<sup>3</sup>, pH 2.41).

## REFERENCES


1. Merrifield, R.B. (1963), J. Am. Chem. Soc., 85, 2149-2153.  
5
2. Barany G. and Merrifield R.B. (1979) in The Peptides, Vol. 2 (Academic Press, N.Y.) 1-284.
3. <sup>a</sup>Atherton, E., Clive, D.L.J. and Sheppard, R.C. (1975), J. Am. Chem. Soc., 97, 6584-6585; <sup>b</sup>Arshady, R., Atherton, E., Clive, D.L.J. and Sheppard, R.C., J. Chem. Soc., Perkin Trans. 1, 1981, 529-537.  
10
4. Atherton, E., Fox, H., Harkiss, D., Logan, C.J., Sheppard, R.C. and Williams, B.J., J. Chem. Soc., Chem. Commun., 1978, 537-539.  
15
5. Chang, C.D. and Meienhofer, J. (1978), Int. J. Peptide Protein Res. 11, 246-249.  
20
6. Atherton, E., Brown, E., Sheppard, R.C. and Rosevear, A., J. Chem. Soc., Chem. Commun., 1981, 1151-1152.
7. Small, P.W., and Sherrington, D.C., J. Chem. Soc., Chem. Commun., 1989, 1589-1591.  
25
8. Rapp, W., Zhang, L., Häbich, R. and Bayer, E. (1988) in Peptides, Proc. of 20'th Eur. Pept. Symp., (Jung, G. ed., 1989 Walter de Gruyter and Co., Berlin) 199-201.  
30
9. Zalipsky, S., Albericio, F. and Barany, G. (1985) in Peptides: Structure and Function, Proc. of 9'th Am. Pept. Symp. (Deber, C.M., Hruby, V.J., Kopple, K.D. eds., Pierce Chemical Company, Illinois) 257-260.  
35
10. Berg, R., Amdal, K., Pedersen, W.B., Holm, A., Tam,

J.P. and Merrifield R.B. (1989), J. Am. Chem. Soc., III, 8024-8026.

11. Daniels, S.B., Bernatowicz, M.S., Coull, J.M. and  
5 Köster, H. (1989), Tetrahedron Lett., 30, 4345-4348.
12. Eichler, J., Beinert, A., Stierandova, A. and Lebl, M. (1991), Peptide Research, 4, 296-307.
- 10 13. Trijasson, P., Frère, Y., and Gramain, P., Makromol. Chem., Rapid Commun., 1990, 11, 239-243.
14. Kanda, P., Kennedy, R.C. and Sparrow, J.T. (1991),  
15 Int. J. Pept. Prot. Res., 38, 385-391.
- 15 15. Rink, H. (1987), Tetrahedron Lett., 28, 3787-3790.
16. Knorr, R., Trzeciak, A., Bannwarth, W., and Gillessen, D. (1989), Tetrahedron Lett. 30, 1927-1930.
- 20 17. Atherton, E., Holder, J.L., Meldal, M., Sheppard, R.C., and Valerio, R.M., J. Chem. Soc., Perkin Trans. 1, 1988, 2887-2894.
- 25 18. Cameron, L.R., Holder, J.L., Meldal, M. and Sheppard, R.C., J. Chem. Soc., Perkin Trans. 1, 1988, 2895-2901.
19. Cameron, R.L., Meldal, M. and Sheppard, R.C., J. Chem. Soc., Chem. Commun., 1987, 270-272. The reaction times  
30 are twice that observed visually, matching the sensitivity and reaction times as observed with the solid phase spectrophotometer.
20. Atherton, E. and Sheppard, R.C. (1989) in Solid Phase  
35 Peptide Synthesis, A Practical Approach (IRL, Oxford University Press, Oxford), 63-86.

## PATENT CLAIMS

1. A crosslinked polyethylene or polypropylene glycol containing polymer formed by radical copolymerization of derivatized polyethylene glycol or polypropylene glycol bis-end substituted with a moiety selected from the group consisting of acryloylalkyl, acryloylaryl, acrylamidoalkyl and acrylamidoaryl with an acrylic amide, nitrile or ester.
2. A polymer according to claim 1 which is formed by copolymerization of a derivatized polyethylene glycol of the formula




I

wherein n is an integer of from 4 to 2000, q is zero or 1, and R is



where s, t and u each is zero or an integer of 1-10, and each R' is H, alkyl, aralkyl or aryl, said aralkyl or aryl optionally being ring substituted with alkyl, hydroxy, mercapto, nitro, amino, mono- or dialkylamino, or halogen, with an acrylic compound of the formula




III

wherein R<sup>1</sup> is -CY-X-R<sup>5</sup> or -CN, and R<sup>2</sup>, R<sup>3</sup> and R<sup>4</sup> each is H, alkyl, aralkyl, aryl, -CY-X-R<sup>5</sup> or -CN, where Y is O or S, X is O, S or NR<sup>6</sup>, R<sup>5</sup> is alkyl, aralkyl or aryl, and R<sup>6</sup> is H or


$R^5$ , and optionally with a spacer molecule comprising functional groups for the attachment of peptides, proteins, nucleotides or saccharides.

- 5 3. A polymer according to claim 2 which incorporates a spacer comprising functional groups selected from the group consisting of amino, alkylamino, hydroxy, carboxyl, mercapto, sulfeno, sulfinio, sulfo and derivatives thereof.
- 10 4. A polymer according to claim 2 which is formed by copolymerization of a derivatized polyethylene glycol of the formula I, wherein n, q and R are as defined in claim 2, with an acrylamide of the formula



3

and with a spacer molecule of the formula



I I


wherein m is an integer of from 4 to 2000, and q and R are as defined for formula I in claim 2.

- 35 5. A polymer according to claim 4 which is composed of 60% of bis-2-acrylamidoprop-1-yl-PEG<sub>1900</sub> (1), 20% of 2-acrylamidoprop-1-yl[2-aminoprop-1-yl]-PEG<sub>300</sub> (2) and 20% of N,N-dimethyl acrylamide (3).



6. A polymer according to claim 4 derivatized with any of the linkers normally used in peptide synthesis.

7. A polymer according to claim 6 said linker being 4-[fluorenylmethyloxycarbamido(2,4-dimethoxyphenyl)methyl]-phenoxyacetic acid of the formula



4

15 4-hydroxymethylphenoxyacetic acid, 4-hydroxymethylbenzamide or 4-hydroxymethyl-3-nitrobenzamide.

8. A solid support for continuous flow or batchwise synthesis of peptides said support comprising a polymer according to any one of claims 1-4.

9. A solid support for continuous flow or batchwise synthesis of oligonucleotides said support comprising a polymer according to any one of claims 1-4.

10. A solid support for the synthesis of oligosaccharides said support comprising a polymer according to any one of claims 1-4.

11. A solid support according to any one of claims 8-10 said support being suitable for synthesis by enzymatic reactions.

12. A solid support according to claim 10 for enzymatic synthesis of oligosaccharides with glycosyltransferases.

13. A solid support for the immobilization of proteins said support comprising a polymer according to any one of claims

1-4.

14. A resin for application in chromatographic separations  
said resin comprising a polymer according to any one of  
5 claims 1-4.

15. A method of continuous flow or batchwise synthesis of  
a peptide wherein the peptide during the synthesis is  
attached to a solid support comprising a polymer according  
10 to any one of claims 1-4 and at the end of the synthesis is  
cleaved from said solid support.

16. A method of continuous flow or batchwise synthesis of  
an oligonucleotide wherein the oligonucleotide during the  
15 synthesis is attached to a solid support comprising a  
polymer according to any one of claims 1-4 and at the end  
of the synthesis is cleaved from said solid support.

17. A method of continuous flow or batchwise synthesis of  
20 an oligosaccharide wherein the oligosaccharide during the  
synthesis is attached to a solid support comprising a  
polymer according to any one of claims 1-4 and at the end  
of the synthesis is cleaved from said solid support.

25 18. A method according to any one of claims 15-17 wherein  
the synthesis involves an enzymatic reaction.


19. A method according to claim 17 for enzymatic synthesis  
of an oligosaccharide with a glycosyltransferase.  
30

20. A method of immobilizing a protein wherein the protein  
is attached to a solid support comprising a polymer accor-  
ding to any one of claims 1-4.

35 21. A method of performing chromatographic separations which  
comprises the use of a chromatographic resin comprising a  
polymer according to any one of claims 1-4.

1/4


Polydimethyl  
Acrylamide




Polyethylene glycol (PEG)



*FIG. 1*



$$n=45, m=6$$



*FIG. 2*

3/4

H-Val-Gln-Ala-Ala-Ile-Asp-Tyr-Ile-Asn-Gly-NH<sub>2</sub>

5





FIG. 3



**FIG. 4**

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 93/00051

## A. CLASSIFICATION OF SUBJECT MATTER

IPC5: C08F 283/06, C07K 1/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC5: C08F, C07K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CLAIMS, WPI, CA, EDOC

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	TETRAHEDRON LETTERS, Volume 33, No 21, 1992, Morten Meldal et al, "PEGA: A flow stable polyethylene glycol dimethyl acrylamide copolymer for solid phase synthesis" page 3077 - page 3080  --	1-21
A	J. CHEM. SOC., CHEM. COMMUN., Volume 21, 1989, Philip W. Small et al, "Design and application of a new rigid support for high efficiency continuous-flow peptide synthesis" page 1589 - page 1591  --	1-21

☒ Further documents are listed in the continuation of Box C.
 ☐ See patent family annex.

\* Special categories of cited documents:

"A" document defining the general state of the art which is not considered to be of particular relevance

"B" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&amp;" document member of the same patent family

Date of the actual completion of the international search

26 May 1993

Date of mailing of the international search report

27 -05- 1993

 Name and mailing address of the ISA/  
 Swedish Patent Office  
 Box 5055, S-102 42 STOCKHOLM  
 Facsimile No. +46 8 666 02 86

Authorized officer

 Sofia Nikolopoulou  
 Telephone No. +46 8 782 25 00

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/DK 93/00051

## C (Continuation): DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	TETRAHEDRON LETTERS, Volume 30, No 33, 1989, Scott B. Daniels et al, "Membranes as solid supports for peptide synthesis" page 4345 - page 4348  -----	1-21